News Coverage 10.20.20 Share on Twitter Share on Facebook Share on LinkedIn The international neoantigen initiative Tumour Neoantigen Selection Alliance (TESLA) has identified key parameters for immunotherapy advancement. Related Announcement, Partner Highlight, Press Release PICI, Immunai to Build Landmark Cancer Dataset Announcement, Our Impact PICI at AACR 2025: Data, Direction, Impact Announcement, Press Release Dr. Ira Mellman Joins PICI as President of Research